Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience
- PMID: 38410247
- PMCID: PMC10894993
- DOI: 10.3389/fcvm.2024.1345608
Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience
Abstract
Transthyretin amyloidosis (ATTR) is a condition defined by accumulation of insoluble transthyretin amyloid deposits in multiple organs, especially in the peripheral nerve and heart muscle. ATTR may result from transthyretin mutations (variant ATTR or ATTRv) or may occur with normal transthyretin genotype (wild type ATTR or ATTRwt). ATTRwt was previously known as "senile amyloidosis" and causes cardiomyopathy which may lead to heart failure with a preserved ejection fraction, affecting predominantly elderly men. The exact prevalence of ATTRwt in the general population remains unclear, but its occurrence may be underestimated in women. It was observed that a proportion of ATTRwt cardiomyopathy patients may develop slowly progressing neuropathy that is milder and indolent in comparison with typical progressive neuropathy associated with ATTRv. Furthermore, the causality of neuropathy is often uncertain in patients with ATTRwt. Neuropathy symptoms, including distal sensory loss, unsteadiness and (neuropathic) pain are common in elderly patients with multiple potential causes, and as ATTRwt patients are typically older, relatively high prevalence of peripheral neuropathy is expected with frequent comorbidities. Relatively high prevalence of ATTRwt in elderly population contrasts few documented cases of neuropathy caused by ATTRwt, and there is uncertainty whether ATTRwt neuropathy is an infrequent occurrence or a significant manifestation of multisystemic ATTRwt. We review neurologic and musculoskeletal manifestations of ATTRwt and present clinical features of a single center cohort of ATTRwt patients with suspected peripheral neuropathy.
Keywords: carpal tunnel syndrome; dysautonomia; musculoskeletal disorders (MSD); peripheral neuropathy (PN); transthyretin amyloidosis (ATTR); wild type amyloidosis.
© 2024 Živković, Lacomis and Soman.
Conflict of interest statement
SŽ: Consultancy with Alnylam Pharmaceuticals and Astra Zeneca. PS: Consultancy with Alnylam Pharmaceuticals, Bridgebio, Pfizer, Spectrum Dynamics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.Amyloid. 2022 Jun;29(2):92-101. doi: 10.1080/13506129.2021.2014448. Epub 2022 Jan 7. Amyloid. 2022. PMID: 34994254
-
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.JACC Heart Fail. 2021 Feb;9(2):115-123. doi: 10.1016/j.jchf.2020.09.011. Epub 2020 Dec 9. JACC Heart Fail. 2021. PMID: 33309574
-
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.Amyloid. 2022 Mar;29(1):14-22. doi: 10.1080/13506129.2021.1976751. Epub 2021 Oct 11. Amyloid. 2022. PMID: 34632904
-
Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.J Nucl Cardiol. 2023 Aug;30(4):1420-1426. doi: 10.1007/s12350-022-02990-x. Epub 2022 May 17. J Nucl Cardiol. 2023. PMID: 35581484 Free PMC article. Review.
-
Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review.BMC Musculoskelet Disord. 2023 Sep 22;24(1):751. doi: 10.1186/s12891-023-06853-5. BMC Musculoskelet Disord. 2023. PMID: 37740174 Free PMC article.
Cited by
-
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS.Cardiol Ther. 2025 Jul 9. doi: 10.1007/s40119-025-00421-9. Online ahead of print. Cardiol Ther. 2025. PMID: 40632476
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials